Drugs Made In America Acquisition II Corp. Ordinary Shares
DMII
NASDAQ Global Market10.08
USD
-0.01
- -
CIK
0002040475
ISIN
KYG2851K1040
CUSIP
G2851K104
Return %
Stock
S&P500
1Y
2.02
18.21
3Y
2.02
63.29
5Y
2.02
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Roger Bendelac
- Full Time Employees
- 2
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 1 East Broward Boulevard New York NY United States of America 33301
- IPO Date
- Dec 4, 2025
- CIK
- 0002040475
- Website
- dmaacorp.com
- Similar Companies
- Business
- Drugs Made In America Acquisition II Corp. (Nasdaq: DMII) is a blank check company, or special purpose acquisition company (SPAC), incorporated in the Cayman Islands as an exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses; while it may pursue targets across industries and geographies, the company intends to focus primarily on the pharmaceutical sector, particularly firms developing strategic domestic manufacturing technologies for critical drugs to mitigate U.S. medical supply chain risks and reduce reliance on production concentrated in certain foreign regions. The company has not yet identified or engaged in substantive discussions with any specific business combination target. Headquartered at 1 East Broward Boulevard, Suite 700, Fort Lauderdale, Florida 33301, United States, the company was founded on August 23, 2024, with Lynn Stockwell serving as Chief Executive Officer and Executive Chair. In September 2025, the company completed its initial public offering of 50 million units at $10.00 per unit, raising $500 million in gross proceeds before underwriting discounts and expenses—the largest SPAC IPO of 2025 to date—with Cantor Fitzgerald & Co. acting as sole book-running manager and receiving a 45-day over-allotment option for up to 7.5 million additional units. On December 3, 2025, the company announced that holders of its IPO units may elect to separately trade ordinary shares (under ticker DMII) and rights (under DMIIR) on the Nasdaq Global Market, while unseparated units continue trading as DMIIU; rights entitle holders to one-tenth of an ordinary share upon consummation of an initial business combination. The company has up to 24 months from IPO closing to complete a business combination, with net proceeds held in trust invested in U.S. Treasury obligations, or it will liquidate and return funds to public shareholders. As of late 2025, no partnerships, acquisitions, funding rounds beyond the IPO, new product launches, or other major strategic shifts have been announced.
Drugs Made In America Acquisition II (NASDAQ:DMII) Trading 0.1% Higher – What’s Next?